• 12399 - Simpson
    Dupilumab Treatment in Patients With Atopic Hand and Foot Dermatitis: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
    Eric L. Simpson, Jonathan I. Silverberg, Margitta Worm, Golara Honari, Koji Masuda, Ewa Sygula, Jennifer Maloney, Jing Xiao, Ariane Dubost-Brama, Ashish Bansal
    Poster Abstract

  • 12400 - Somani
    The 40-gene expression profile (40-GEP) test allows for an improved prognostication of the likelihood of metastasis in patients with T1 cutaneous squamous cell carcinoma (cSCC) with high-risk factors
    Ally‐Khan Somani, MD, PhD; Javier Cañueto MD, PhD; Vincent Smith, DNP, ANP-C; Andrew Berg, NP-C; Alison L. Fitzgerald, PhD; Jennifer J. Siegel, PhD; Anesh Prasai, PhD; Sherrif F, Ibrahim, MD, PhD; Sarah T. Arron, MD, PhD
    Poster Abstract

  • 12401 - Stein Gold
    Consistent Skin Clearance With Guselkumab Treatment for up to 5 Years in Patients With Moderate to Severe Psoriasis Irrespective of Baseline Disease Extent or Severity in the VOYAGE 1 and 2 Studies
    L. Stein Gold, B. Strober, J.F. Merola, A.B. Gottlieb, O. Choi, K. Rowland, D. Chan, Y. You, L. Park-Wyllie, K.A. Papp, R.G. Langley, R. Bissonnette, K.B. Gordon, A.W. Armstrong, J.G. Krueger, M. Lebwohl
    Poster Abstract

  • 12402 - Stein Gold
    Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug
    Linda Stein Gold; Leon H Kircik; Emil A Tanghetti; Hilary Baldwin; Zoe D Draelos; Michael Gold; Edward Lain; David M Pariser; Neil Sadick; Radhakrishnan Pillai; Varsha Bhatt
    Poster Abstract

  • 12337 - Strober
    Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
    Luis Puig, Andrew Blauvelt, Diamant Thaçi, Boni Elewski, Maggie Wang, Veerle Vanvoorden, Delphine Deherder, Fabienne Staelens, Susanne Wiegratz,Carle Paul
    Poster Abstract

  • 12403 - Strober
    Longitudinal improvement in patient-reported outcomes with deucravacitinib in moderate to severe plaque psoriasis: Results from the POETYK PSO-1 and POETYK PSO-2 randomized phase 3 clinical trials through week 52
    Bruce Strober, April W. Armstrong, Joe Zhuo, Brandon Becker, Yichen Zhong, Jennifer L. Beaumont, Tan P. Pham, Andrew Napoli, Subhashis Banerjee, Kim A. Papp
    Poster Abstract

  • 12404 - Sugarman
    An Evaluation of the Phototoxic and Photoallergic Potential of Microencapsulated Benzoyl Peroxide and Tretinoin
    Jeffrey Sugarman, MD, Rinat Mizrahi, MsC, Ofra Levy-Hacham, PhD
    Poster Abstract

  • 12405 - Vanderhoff
    This is the title
    Michelle Vanderhoff
    Poster Abstract

  • 12406 - Warren
    Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 2-year efficacy by prior biologic treatment in the phase 3 POETYK PSO program
    Richard B. Warren, April W. Armstrong, Shinichi Imafuku, Carle Paul, Leon Kircik, Subhashis Banerjee, Elizabeth Colston, Thomas Scharnitz, Tao Wang, Bruce Strober
    Poster Abstract